These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 7887641)

  • 21. [Late phase II study of CGS16949A, a new aromatase inhibitor--a multicentral cooperative study (Western Japan Group)].
    Wada T; Nomura Y; Oohashi Y; Abe O; Koyama H; Takashima S
    Gan To Kagaku Ryoho; 1994 Mar; 21(4):485-93. PubMed ID: 8129389
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Treatment of uterine leiomyoma with depot leuprorelin acetate (Enantone-Gyn monthly depot). Effect on leiomyoma volume and operability. German Leuprorelin Study Group].
    Stolz W; Pfützenreuter N
    Zentralbl Gynakol; 1997; 119(10):468-75. PubMed ID: 9432825
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Endocrine therapy for advanced or recurrent breast cancer].
    Sonoo H; Kurebayashi J
    Gan To Kagaku Ryoho; 2001 Jul; 28(7):909-16. PubMed ID: 11478139
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study.
    Celio L; Martinetti A; Ferrari L; Buzzoni R; Mariani L; Miceli R; Seregni E; Procopio G; Cassata A; Bombardieri E; Bajetta E
    Anticancer Res; 1999; 19(3B):2261-8. PubMed ID: 10472341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of prostatic cancer with TAP-144-SR, a depot preparation of LH-RH agonist (leuprolide).
    Isurugi K; Niijima T; Akaza H; Aso Y; Koiso K; Fuse M; Okada K; Usami M; Ohashi T; Ueda T;
    J Chemother; 1989 Jul; 1(4 Suppl):1237-41. PubMed ID: 16312848
    [No Abstract]   [Full Text] [Related]  

  • 26. Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma.
    Recchia F; Saggio G; Amiconi G; Di Blasio A; Cesta A; Candeloro G; Rea S
    Cancer; 2006 Feb; 106(3):514-23. PubMed ID: 16388519
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prospective randomized study comparing the GnRH-agonist leuprorelin acetate and the gestagen lynestrenol in the treatment of severe endometriosis.
    Regidor PA; Regidor M; Schmidt M; Ruwe B; Lübben G; Förtig P; Kienle E; Schindler AE
    Gynecol Endocrinol; 2001 Jun; 15(3):202-9. PubMed ID: 11447732
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A phase II study of weekly paclitaxel for advanced or recurrent breast cancer].
    Wada Y; Otoshi M; Jitsuko A; Nishikawa H; Takahara S; Tsubono M; Imai S
    Gan To Kagaku Ryoho; 2007 Jul; 34(7):1041-5. PubMed ID: 17637539
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A case of premenopausal breast cancer showing remarkable elevation of serum alkaline phosphatase level during treatment with LH-RH analog.
    Ito K; Komatsu A; Kanai T; Koyama H; Hama Y; Shingu K; Fujimori M; Amano J
    Breast J; 2005; 11(6):523-4. PubMed ID: 16297128
    [No Abstract]   [Full Text] [Related]  

  • 30. [An early phase II clinical study of S-1 in patients with breast cancer. S-1 Cooperative Study Group (Breast Cancer Working Group)].
    Taguchi T; Morimoto K; Horikoshi N; Takashima S; Toge T; Kimura M; Sano M; Aoyama H; Ota J; Noguchi S
    Gan To Kagaku Ryoho; 1998 Jun; 25(7):1035-43. PubMed ID: 9644319
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Response of patients with advanced prostatic cancer to administration of somatostatin analog RC-160 (vapreotide) at the time of relapse.
    González-Barcena D; Schally AV; Vadillo-Buenfil M; Cortez-Morales A; Hernández L V; Cardenas-Cornejo I; Comaru-Schally AM
    Prostate; 2003 Aug; 56(3):183-91. PubMed ID: 12772187
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Late phase II clinical study of vinorelbine monotherapy in advanced or recurrent breast cancer previously treated with anthracyclines and taxanes.
    Toi M; Saeki T; Aogi K; Sano M; Hatake K; Asaga T; Tokuda Y; Mitsuyama S; Kimura M; Kobayashi T; Tamura M; Tabei T; Shin E; Nishimura R; Ohno S; Takashima S
    Jpn J Clin Oncol; 2005 Jun; 35(6):310-5. PubMed ID: 15930037
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Phase II study of CGS16949A, a new aromatase inhibitor--a dose finding study].
    Tominaga T; Abe O; Asaishi K; Abe R; Enomoto K; Kajiwara T; Yoshida M; Wada T; Nomura Y
    Gan To Kagaku Ryoho; 1994 Mar; 21(4):465-75. PubMed ID: 8129387
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A comparative study between low-dose and high-dose medroxyprogesterone acetate (MPA) in the treatment of advanced and recurrent breast cancer--in relation to dose, serum concentration and response. Osaka Breast Cancer Research Group].
    Furukawa J; Yayoi E; Takatsuka Y; Aikawa T; Maeura Y; Kobayashi T; Miyauchi K; Kotsuma Y
    Gan To Kagaku Ryoho; 1997 May; 24(7):815-21. PubMed ID: 9170519
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Phase II study of NK 622 (toremifene citrate) in advanced breast cancer, a multicentral cooperative dose finding study].
    Tominaga T; Abe O; Izuo M; Nomura Y
    Gan To Kagaku Ryoho; 1993 Jan; 20(1):79-90. PubMed ID: 8422189
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Assessment of goserelin treatment in adjuvant therapy for premenopausal patients with breast cancer in Japan-zoladex breast cancer study group trial-B].
    Mitsuyama S; Nomura Y; Ohno S; Miyauchi M; Yamamoto N; Kimura T; Saku M; Miura S; Yoshikawa N; Tsujinaka T; Koh J; Ishida T; Abe O; Ohashi Y
    Gan To Kagaku Ryoho; 2005 Dec; 32(13):2071-7. PubMed ID: 16352931
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Circulating hormone levels in breast cancer patients. correlation with serum tumor markers and the clinical and biological features of the tumors.
    Hernández L; Nuñez-Villarl MJ; Martínez-Arribas F; Pollán M; Schneider J
    Anticancer Res; 2005; 25(1B):451-4. PubMed ID: 15816610
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [A comparison of the quality of life of prostatic cancer patients under slow releasing LH-RH analogue (TAP-144SR Depot) treatment or synthetic estrogen treatment].
    Oishi K; Arai Y; Takeuchi H; Yoshida O
    Hinyokika Kiyo; 1991 Sep; 37(9):1017-22. PubMed ID: 1785408
    [TBL] [Abstract][Full Text] [Related]  

  • 39. LH-RH agonists offer very good protection against the adverse gynaecological effects induced by tamoxifen.
    Berlière M; Galant C; Marques G; Piette P; Duck L; Fellah L; Donnez J; Machiels JP
    Eur J Cancer; 2004 Aug; 40(12):1855-61. PubMed ID: 15288287
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Skin reaction induced by subcutaneous injection of LH-RH analogue].
    Segawa N; Nishida T; Hamada S; Azuma H; Katsuoka Y; Nozaki K; Tsuji M
    Hinyokika Kiyo; 2007 Oct; 53(10):695-8. PubMed ID: 18018584
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.